Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Aprinoia to Start China Trial of PET Tracing Agent for Alzheimer's

publication date: Oct 28, 2020

Aprinoia Therapeutics was approved to start a China Phase III trial of its PET imaging tracer that targets abnormal tau protein aggregates in the brain. 18F-APN-1607 is a new-gen tau tracer designed to recognize tau proteins in their pathological aggregated states, but not normal physiological ones. The Phase III trial will evaluate the ability of 18F-APN-1607 to differentiate patients with Mild Cognitive Impairment (MCI) and other stages of Alzheimer's disease from healthy subjects. Aprinoia is headquartered in Taipei, with a China subsidiary in Suzhou. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital